T cell leukemia homeobox 3Genealiases: HOX11L2 · RNX
Q-omics provides the consensus-scored TLX3 profile across patient tissues and cancer cell-line models. TLX3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, TLX3 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, TLX3 RNA expression shows 9,449 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, HNSC, and TGCT as cancer lineages where TLX3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLX3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLX3 survival associations across molecular data types. TLX3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLX3 RNA expression–survival associations across cancer types. High TLX3 expression shows unfavorable associations in BRCA, KIRP, ESCA and THYM, but favorable associations in SCLC and HNSC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for TLX3 RNA expression.
This table summarizes TLX3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TLX3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLX3 shows lower tumor expression in STAD and THCA and higher tumor expression in HNSC, LUSC, UCEC and BRCA. The HNSC box plot shows higher TLX3 RNA expression in tumor versus normal tissue (log2 FC = +0.942, t-test p < 0.001).
This table shows molecular features associated with TLX3 in patient tissues and cancer cell lines. In patient samples, TLX3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TLX3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
